We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

20 hedge funds and large institutions have $988K invested in Titan Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

113% more capital invested

Capital invested by funds: $464K → $988K (+$524K)

33% more funds holding

Funds holding: 15 → 20 (+5)

0.07% more ownership

Funds ownership: 0.1% → 0.17% (+0.07%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

26% less call options, than puts

Call options by funds: $741K | Put options by funds: $999K

Holders
20
Holders Change
+5
Holders Change %
+33.33%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
3
Closed
2
Calls
$741K
Puts
$999K
Net Calls
-$258K
Net Calls Change
-$494K

Top Buyers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
+$239K
2
GCP
GSA Capital Partners
United Kingdom
+$132K
3
CS
Credit Suisse
Switzerland
+$76.8K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$60.2K
5
UBS Group
UBS Group
Switzerland
+$57.6K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$19.6K
2
TI
tru Independence
Oregon
-$11.5K
3
Citadel Advisors
Citadel Advisors
Florida
-$10.7K
4
ASN
Advisory Services Network
Georgia
-$7K
5
TRCT
Tower Research Capital (TRC)
New York
-$3.84K
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
1
Group One Trading
Illinois
$218K +$239K +3,616 +9,040%
Vanguard Group
2
Vanguard Group
Pennsylvania
$217K +$53.3K +805 +28%
GCP
3
GSA Capital Partners
United Kingdom
$119K +$132K +1,991 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$105K – – –
UBS Group
5
UBS Group
Switzerland
$70K +$57.6K +870 +287%
CS
6
Credit Suisse
Switzerland
$69K +$76.8K +1,160 New
Citadel Advisors
7
Citadel Advisors
Florida
$57K -$10.7K -162 -14%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$54K +$60.2K +910 New
Millennium Management
9
Millennium Management
New York
$50K +$55.9K +844 New
TRCT
10
Tower Research Capital (TRC)
New York
$20K -$3.84K -58 -15%
Simplex Trading
11
Simplex Trading
Illinois
$9K +$10.1K +152 New
APA
12
American Portfolios Advisors
New York
$69 – – –
Bank of America
13
Bank of America
North Carolina
– -$19.6K -296 -98%
TI
14
tru Independence
Oregon
– -$11.5K -175 Closed
ASN
15
Advisory Services Network
Georgia
– -$7K -100 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– +$66 +1 New
JP Morgan Chase
17
JP Morgan Chase
New York
– +$265 +4 New

TTNP Hedge Fund Activity: Q1 2021 in Review

20 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2021, worth a combined $988K — up 113% from $464K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TTNP positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Group One Trading, adding an estimated $239K. The largest seller was Bank of America, cutting an estimated $19.6K.

  • 20 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2021, up from 15 in Q4 2020.
  • Funds reported $988K of Titan Pharmaceuticals stock for Q1 2021, up 113% quarter-over-quarter.
  • 7 funds opened new Titan Pharmaceuticals positions in Q1 2021 and 2 closed out, a net change of +5 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2021 was Group One Trading, an estimated $239K added.
  • The largest Titan Pharmaceuticals seller in Q1 2021 was Bank of America, an estimated $19.6K sold.

Based on aggregated 13F filings for Q1 2021.